Medical News

RSS

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Merck, known as MSD outside of the United States and Canada, today announced new data from HIV/HCV co-infected patients in the ongoing C-WORTHY Study, a Phase 2 clinical trial evaluating the efficacy and safety of Merck's all-oral, once-daily regimen combining MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor.

5 Mar 2014

Cross Country Healthcare's consolidated revenue decreases 2% to $109.2 million in Q4 2013

Cross Country Healthcare, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2013.

5 Mar 2014

Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Verastem, Inc., focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today presented preliminary data from an ongoing First-in-Asia Phase 1 trial of VS-6063 in Japanese patients with advanced solid tumors, including one patient with mesothelioma. The Phase 1 study assessed the safety and pharmacokinetics of single agent VS-6063.

5 Mar 2014

Bruker’s new TopSolids™ software provides accelerated workflow in solid-state NMR for the characterization of protein structures

At Pittcon 2014, Bruker introduced TopSolids™, a new intuitive, workflow-based software package for solid-state NMR in structural biology that provides menu-based, automated setup and acquisition of the most advanced multinuclear multi-dimensional NMR experiments.

5 Mar 2014

Drug abuse does not always lead to psychosis readmission

Cannabis or stimulant abuse disorders do not necessarily predict a negative outcome for patients with first-episode psychosis, Australian researchers report.

5 Mar 2014

Diagnostic errors common among patients with bipolar disorder

Russian study data bolster the existing body of evidence showing that bipolar disorder is often misdiagnosed as depression.

5 Mar 2014

Bio-Rad announces release of beta version of the USP Spectral Library

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a multinational manufacturer and distributor of life science research and clinical diagnostic products, today announced the release of beta version of USP Spectral Library™ powered by Bio Rad's KnowItAll® software technology platform for spectral analysis, identification, search, data management, and reporting.

From Bio-Rad Laboratories 5 Mar 2014

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

Cystic fibrosis is a rare, life-shortening genetic disease for which there is no cure. It affects more than 75,000 people worldwide. In CF, thick, sticky mucus blocks the passages in many organs, leading to a variety of symptoms. In particular, mucus builds up and clogs airways in the lungs making it easier for bacteria to grow.

5 Mar 2014

APA to recognize employers with Psychologically Healthy Workplace Award

The American Psychological Association will recognize seven employers for their efforts to promote employee well-being and organizational performance at its ninth annual Psychologically Healthy Workplace Awards in Washington, D.C., on Saturday, March 8.

5 Mar 2014

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Agenus Inc., a biopharmaceutical company developing a portfolio of immuno-oncology candidates, including checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants, today announced its financial results and business highlights for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a Phase 2/3 clinical trial of Glassia®, the Company's proprietary human Alpha-1 Antitrypsin (AAT), to treat newly diagnosed pediatric patients with type 1 diabetes (T1D).

5 Mar 2014

Metabolon agrees to provide biochemical profiling services to Human Longevity

Metabolon, Inc., the world's leading commercial-stage metabolomics company, announces the signing of an agreement with newly-launched Human Longevity Inc., whereby Metabolon will provide biochemical profiling services to assist HLI in its mission to tackle diseases of aging by building the world's largest and most complete human genotype, microbiome and phenotype database.

5 Mar 2014

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

Curie-Cancer, the body responsible for developing Institut Curie’s industry partnership activities, and DNA Therapeutics, a biopharmaceutical company that is developing a new class of cancer drugs, are renewing their partnership.

5 Mar 2014

POZEN reports total revenue of $4.7 million for fourth quarter 2013

POZEN Inc., a pharmaceutical company committed to transforming medicine that transforms lives, today announced results for the fourth quarter and year ended December 31, 2013.

5 Mar 2014

First Edition: March 5, 2014

Today's headlines include reports about President Barack Obama's 2015 budget as well as the latest state-level Medicaid expansion developments.

5 Mar 2014

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Great Lakes NeuroTechnologies announced today they have received a new allowance of claims from the U.S. Patent Office, the company’s fourth in the past eight months focused on technology for Parkinson’s disease diagnostics and treatment.

5 Mar 2014

Minimally invasive surgery outcomes show favorable results in low back pain patients

Beaumont research findings published in the February online issue of Spine shows that patients who have a low back surgery called minimally invasive transforaminal lumbar interbody fusion, end up better off in many ways than patients who have more invasive surgery to alleviate debilitating pain.

5 Mar 2014

Research shows depletion of cholesteryl ester impairs prostate cancer aggressiveness

Researchers have discovered a link between prostate cancer aggressiveness and the accumulation of a compound produced when cholesterol is metabolized in cells, findings that could bring new diagnostic and treatment methods.

5 Mar 2014

Queensland scientists endeavor to stop spread of metastatic disease

Queensland scientists are working to stop the spread of one of the deadliest forms of skin cancer thanks to a $200,000 research grant awarded by Cancer Council Queensland.

5 Mar 2014

$Meta-analysis study shows association between BTMs s-CTX, s-PINP and risk of future fractures$

Meta-analysis study shows association between BTMs s-CTX, s-PINP and risk of future fractures

A new study by an International Osteoporosis Foundation (IOF) and International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) scientific working group summarizes the clinical performance of serum procollagen type I N propeptide (s-PINP) and serum C-terminal cross-linking telopeptide of type I collagen (s-CTX) in fracture risk prediction in untreated individuals in prospective cohort studies.

5 Mar 2014

Medical News

Merck announces new data from ongoing C-WORTHY Study in HIV/HCV co-infected patients

Cross Country Healthcare's consolidated revenue decreases 2% to $109.2 million in Q4 2013

Verastem presents preliminary data from VS-6063 Phase 1 trial in Japanese patients with solid tumors

Bruker’s new TopSolids™ software provides accelerated workflow in solid-state NMR for the characterization of protein structures

Drug abuse does not always lead to psychosis readmission

Diagnostic errors common among patients with bipolar disorder

Bio-Rad announces release of beta version of the USP Spectral Library

Treating cystic fibrosis: an interview with Simon Bedson, Senior Vice President and International General Manager at Vertex

APA to recognize employers with Psychologically Healthy Workplace Award

Agenus reports net loss attributable to common stockholders of $5.8 million for Q4 2013

Kamada initiates Phase 2/3 clinical trial of Glassia to treat pediatric patients with T1D

Metabolon agrees to provide biochemical profiling services to Human Longevity

Curie-Cancer, DNA Therapeutics renew partnership to identify new class of cancer drugs

POZEN reports total revenue of $4.7 million for fourth quarter 2013

First Edition: March 5, 2014

GLNT receives allowance of patent for Parkinson's disease monitoring technology

Minimally invasive surgery outcomes show favorable results in low back pain patients

Research shows depletion of cholesteryl ester impairs prostate cancer aggressiveness

Queensland scientists endeavor to stop spread of metastatic disease

Meta-analysis study shows association between BTMs s-CTX, s-PINP and risk of future fractures

Directed enzyme evolution and the Nobel Prize: Making enzymes evolve in the lab

Advancing Motor Neuron Disease Diagnosis with Non-Invasive Ultrasound and AI

How agentic AI is reshaping laboratory workflows

Latest News